title: The chronic oral administration of arginine aspartate decreases secretion of IGF-1 and IGFBP-3 in healthy volunteers.
abstract: To investigate the effect of chronic oral arginine aspartate on the growth hormone (GH), GH-releasing hormone (GHRH), insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) secretions in healthy volunteers. Twenty-three healthy non-athlete volunteer males were administered arginine aspartate (30 g) orally once daily at 21:00 h for 21 consecutive days. Subjects were hospitalized on days 0, 1, 3, 5, 7, 14 and 21 of treatment. At each hospitalization, concentrations of GHRH, GH, IGF-1 and IGFBP-3 were measured over 4 h after arginine aspartate intake. GH, IGF-1 and IGFBP-3 concentrations were also determined over 12 h at days 0, 1 and 21. Compared with day 1, 4 h GH levels dropped at day 5 and subsequently rose to levels not significantly different from initial ones. The latter was substantiated by 12 h GH levels that did not significantly change from days 1 to 21. GHRH levels were not statistically different, although there was a trend in median values that seemed to inversely mirror those of GH. This dynamic over the course of the study for GH and GHRH was accompanied by a general decrease in IGF-1 and IGFBP-3. In healthy volunteers, a chronic oral treatment with 30 g/day arginine aspartate is followed by a decrease in IGF-1 and IGFBP-3 secretions.
authors.affiliation: Département de Pharmacologie, Université Victor Segalen, 33076 Bordeaux, France.
authors.forename: Sylvie
authors.initials: S
authors.lastname: Blazejewski
authors.forename: Agnès
authors.initials: A
authors.lastname: Georges
authors.forename: Karelle
authors.initials: K
authors.lastname: Forest
authors.forename: Jean-Benoît
authors.initials: JB
authors.lastname: Corcuff
authors.forename: Abdelilah
authors.initials: A
authors.lastname: Abouelfath
authors.forename: Pierre-Olivier
authors.initials: PO
authors.lastname: Girodet
authors.forename: Mamadou
authors.initials: M
authors.lastname: Kamagate
authors.forename: Alain
authors.initials: A
authors.lastname: Jacquet
authors.forename: Odile
authors.initials: O
authors.lastname: Pillet
authors.forename: Laurence
authors.initials: L
authors.lastname: Bordenave
authors.forename: Nicholas
authors.initials: N
authors.lastname: Moore
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001120:Arginine / Q000008:administration & dosage / Q000494:pharmacology*; D001224:Aspartic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D004334:Drug Administration Schedule; D013006:Growth Hormone / Q000187:drug effects / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000187:drug effects* / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D013997:Time Factors; D055815:Young Adult
chemical_list: D018972:Insulin-Like Growth Factor Binding Protein 3; D001224:Aspartic Acid; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D001120:Arginine; C024891:arginine aspartate